Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer
Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda's stock following the FDA's rejection of its stomach condition drug.
Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda
Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory approval, according to people familiar with the matter.
Vanda Pharma Gets Second Unsolicited Acquisition Offer From Cycle Group
Vanda Pharmaceuticals Inc. (VNDA) confirmed on Monday that it received a second unsolicited, non-binding proposal from Cycle Group
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals
UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.
Vanda Shares Climb on Reiterated Cycle Acquisition Offer
Shares have gained 24% since the start of the year. Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct.
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update)
Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda Board’s continued refusal to engage following the receipt of
FiercePharma5h
With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate
In less than a month, Americans will head to the polls—or vote by mail—and elect the next president of the U.S. | While a ...
AI Can Give Pharma More Shots On Goal, But Robust Data And Validation Are Key To Drug Approvals
The underlying issue for pharma companies using AI lies in the quality of the inputs and how AI models are used.
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Big pharma takes on doctors over homebrew cancer treatments
Australia’s top nuclear physicians say their patients will die earlier and in more pain if they are forced to stop making ...
FiercePharma6h
Enhancing ROI with Privacy-Compliant Pharma Marketing: Insights from BranchLab
As the landscape of healthcare advertising evolves, how can brands effectively reach their audiences while ensuring da | ...
Buy Rating Affirmed for AptarGroup on Strong Pharma Prospects and Beauty Segment Rebound
AptarGroup (ATR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Rizzo ...
Indian pharma market grows 5.1 pc in September
The Indian pharma market grew 5.1 per cent (year-on-year) in September, led by cardiac, dermal and anti-diabetic therapies, a ...
devdiscourse1h
UK Stock Indexes Soar Amidst Utility and Pharma Gains
The UK's main stock indexes rose as utilities and pharma stocks drove gains, while gambling firms faced losses amid possible ...
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal
Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious ...